CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies

The prognosis of adults with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains dismal even at this day and age. With salvage chemotherapy, only 29% (range 18 to 44%) of the patients with R/R ALL can be induced into complete remission (CR), with a median overall survival (OS) of 4 ...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Li-Na, Song, Yongping, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855988/
https://www.ncbi.nlm.nih.gov/pubmed/29544528
http://dx.doi.org/10.1186/s13045-018-0593-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855988/
https://www.ncbi.nlm.nih.gov/pubmed/29544528
http://dx.doi.org/10.1186/s13045-018-0593-5

Ejemplares similares